Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1688-1698

  Zhang, Han Ting ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Antidepressant; Brain distribution; cAMP signaling; Phosphodiesterase 4 (PDE4); RNA interference (RNAi); Splice variant

Indexed keywords

2 AMINO 4,5 DIHYDRO 6 METHYL 5 OXO 4 PROPYL 1,2,4 TRIAZOLO[1,5 A]PYRIMIDINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CP 76593; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; IMIPRAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PICLAMILAST; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; PHOSPHODIESTERASE INHIBITOR;

ANIMAL BEHAVIOR; BINDING AFFINITY; BRAIN REGION; CATALYSIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DEPRESSION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; FORCED SWIMMING TEST; GASTROINTESTINAL SYMPTOM; HUMAN; IMMOBILIZATION STRESS; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; VOMITING; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 67650569455     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168092     Document Type: Review

References (155)

1. Sinsheimer RL, Koerner JF. A purification of venom phosphodiesterase. J Biol Chem 1952; 198: 293-6.
2. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-48.
3. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-98.
4. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 2002; 3: 710-8.
5. Conti M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol 2000; 14: 1317-27.
6. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002; 13: 29-35.
7. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999; 63: 1-38.
8. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006; 5: 660-70.
9. Bolger GB, McPhee I, Houslay MD. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem 1996; 271: 1065-71.
10. Nemoz G, Sette C, Conti M. Selective activation of rolipramsensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol 1997; 51: 242-9.
11. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52.
12. Schneider HH, Schmiechen R, Brezinski M, and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986; 127: 105-15.
13. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, et al. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 1992; 267: 1798-804.
14. Zhao Y, Zhang HT, O'Donnell JM. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H] rolipram. J Pharmacol Exp Ther 2003; 305: 565-72.
15. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983; 22: 267-72.
16. Mizokawa T, Kimura K, Ikoma Y, Hara K, Oshino N, Yamamoto T, et al. The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Jpn J Pharmacol 1988; 48: 357-64.
17. Przegalinski E, Bigajska K. Antidepressant properties of some phosphodiesterase inhibitors. Pol J Pharmacol Pharm 1983; 35: 233-40
18. Horowski R, Sastre-y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr Ther Res Clin Exp 1985; 38: 23-39.
19. Fleischhacker WW, Hinterguber H, Bauer H, Pflug B, Berner P, Simhandl C, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992; 26: 59-64.
20. Zhang HT, Huang Y, Jin SLC, Frith SA, Suvarna N, Conti M, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002; 27: 587-95.
21. McLachlan CS, Chen ML, Lynex CN, Goh DL, Brenner S, Tay SK. Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. Arch Neurol 2007; 64: 456-7.
22. Rose GM, Hopper A, De Vivo M, Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005; 11: 3329-34.
23. Blokland A, Schreiber R, Prickaerts J. Improving memory: A role for phosphodiesterases. Curr Pharm Des 2006; 12: 2511-23.
24. Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs R D 2006; 7: 63-71.
25. Parkes JD, Thompson C, Brennan L, Gajraj N, Howcroft B, Ruiz J. Rolipram in Parkinson's disease. Adv Neurol 1984; 40: 563-5.
26. Yang L, Calingasan NY, Lorenzo BJ, Beal MF. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008; 211:311-4.
27. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-46.
28. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005; 310: 1187-91.
29. Siuciak JA, Chapin DS, McCarthy SA, Martin AN. Antipsychotic profile of rolipram: Efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 2007; 192: 415-24.
30. Nakayama T, Asai S, Sato N, Soma M. PDE4D gene in the STRK1 region on 5q12: Susceptibility gene for ischemic stroke. Curr Med Chem 2007; 14: 3171-8.
31. Zee RY, Brophy VH, Cheng S, Hegener HH, Erlich HA, Ridker PM. Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: A prospective, nested case-control evaluation. Stroke 2006; 37: 2012-17.
32. DeMarch Z, Giampa C, Patassini S, Martorana A, Bernardi G, Fusco FR. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis 2007; 25: 266-73.
33. DeMarch Z, Giampa C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008; 30:375-87.
34. Braun NN, Reutiman TJ, Lee S, Folsom TD, Fatemi SH. Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. NeuroReport 2007; 18: 1841-4.
35. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 1995; 282: 71-6.
36. Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, Fukui S, et al. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 1995; 56: PL443-7.
37. Chandrasekaran A, Toh KY, Low SH, Tay SK, Brenner S, Goh DL. Identification and characterization of novel mouse PDE4D isoforms: molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals. Cell Signal 2008; 20: 139-53.
38. Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS, et al. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). J Pharmacol Exp Ther 2007; 322: 600-9.
39. Lynex CN, Li Z, Chen ML, Toh KY, Low RW, Goh DL, et al. Identification and molecular characterization of a novel PDE4D11 cAMP-specific phosphodiesterase isoform. Cell Signal 2008; 20: 2247-55.
40. Mackenzie KF, Topping EC, Bugaj-Gaweda B, Deng C, Cheung YF, Olsen AE, et al. Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochem J 2008; 411: 361-9.
41. Wallace DA, Johnston LA, Huston E, MacMaster D, Houslay TM, Cheung YF, et al. Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol Pharmacol 2005; 67: 1920-34.
42. Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007; 100: 950-66.
43. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004; 25: 158-63.
44. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 2002; 136: 421-33.
45. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 1996; 271: 16526-34
46. Oki N, Takahashi SI, Hidaka H, Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem 2000; 275: 10831-7.
47. Johnston LA, Erdogan S, Cheung YF, Sullivan M, Barber R, Lynch MJ, et al. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J 2004; 380: 371-84.
48. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 2000; 131: 811-9.
49. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 1999; 18: 893-903.
50. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 2000; 275: 16609-17.
51. Gourley SL, Wu FJ, Kiraly DD, Ploski JE, Kedves AT, Duman RS, et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008; 63: 353-9.
52. Qi X, Lin W, Li J, Li H, Wang W, Wang D, et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008; 31: 278-85.
53. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996; 50:891-9.
54. Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997; 9: 227-36.
55. Kaulen P, Bruning G, Schneider HH, Sarter M, Baumgarten HG. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 1989; 503: 229-45.
56. Schmiechen R, Schneider HH, Wachtel H. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacol Ser (Berl) 1990; 102: 17-20.
57. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, et al. Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 1996; 39: 120-5.
58. Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, et al. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol 2007; 573: 93-9.
59. Souness JE, Houghton C, Sardar N, Withnall MT. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 1997; 121: 743-50.
60. Zhao Y, Zhang HT, O'Donnell JM. Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: Dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 2003a; 307: 246-53.
61. Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, et al. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology (Berl) 2006; 186: 209-17.
62. Iwahashi Y, Furuyama T, Tano Y, Ishimoto I, Shimomura Y, Inagaki S. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain. Brain Res Mol Brain Res 1996; 38: 14-24.
63. Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 2000; 20: 349-74.
64. Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 1999; 407: 287-301.
65. Lamontagne, S., Meadows E, Luk P, Normandin D, Muise E, Boulet L, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001; 920: 84-96.
66. DaSilva JN, Lourenco CM, Meyer JH, Hussey D, Potter WZ, Houle S. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging 2002; 29: 1680-3.
67. Dlaboga D, Hajjhussein H, O'Donnell JM. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram. Brain Res 2006; 1096: 104-12.
68. Zhang HT, Frith SA, Wilkins J, O'Donnell JM. Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl) 2001; 159: 89-97.
69. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005; 29: 627-47
70. Gehlert DR, Dawson TM, Yamamura HI, Wamsley JK. Quantitative autoradiography of [3H]forskolin binding sites in the rat brain. Brain Res 1985; 361: 351-60.
71. Poat JA, Cripps HE, Iversen LL. Differences between high-affinity forskolin binding sites in dopamine-rich and other regions of rat brain. Proc Natl Acad Sci USA 1988; 85: 3216-20.
72. O'Donnell JM. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 1993; 264: 1168-78.
73. Zhang HT, O'Donnell JM. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berl) 2000; 150: 311-6.
74. Schneider HH. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol 1984; 33: 1690-3.
75. van Staveren WC, Markerink-van Ittersum M, Steinbusch HW, de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 2001; 888: 275-86.
76. Wachtel H, Löschmann PA, Schneider HH, Rettig KJ. Effects of forskolin on spontaneous behavior, rectal temperature and brain cAMP levels of rats: Interaction with rolipram. Neurosci Lett 1987; 76: 191-6.
77. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2008: 33: 1611-23.
78. Engels P, Abdel'Al S, Hulley P, Lübbert H. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J Neurosci Res 1995; 41: 169-78.
79. Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, Lynch MJ, et al. PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: Role of compartmentalized phosphodiesterases. J Cell Biol 2006; 175: 441-51.
80. Fischmeister R. Is cAMP good or bad? Depends on where it's made. Circ Res 2006; 98: 582-4.
81. Rich TC, Xin W, Mehats C, Hassell KA, Piggott LA, Le X, et al. Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells. Am J Physiol Cell Physiol 2007; 292: C319-31.
82. Baillie GS, Houslay MD. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 2005; 17: 129-34.
83. Nestler EJ, Alreja M, Aghajanian GK. Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 1999; 46: 1131-9.
84. Ariumi H, Saito R, Nago S, Hyakusoku M, Takano Y, Kamiya H. The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett 2000; 286: 123-6.
85. Koob GF. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13: 177-84.
86. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, et al. Rolipram in major depressive disorder: Results of a doubleblind comparative study with imipramine. Pharmacopsychiatry 1989; 22: 156-60.
87. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-90.
88. Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: Is rolipram as effective as amitriptyline. Eur J Clin Pharmacol 1991; 40: 127-9.
89. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324-35.
90. Renau TE. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: Opportunities and challenges. Curr Opin Investig Drugs 2004; 5: 34-9.
91. Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003; 23: 419-30.
92. Saccomano NA, Vinick FJ, Koe BK, Nielsen JA, Whalen WM, Meltz M, et al. Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones. J Med Chem 1991; 34: 291-8.
93. O'Donnell JM, Frith S. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 1999; 63: 185-92.
94. O'Donnell JM, Marek GJ, Seiden LS. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 2005; 29: 785-98.
95. Overstreet DH, Friedman E, Mathé AA, Yadid G. The Flinders Sensitive Line rat: A selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005; 29: 739-59.
96. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 1988; 238: 2-6.
97. Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 1997; 75: 275-81.
98. Ohsawa F, Yamauchi M, Nagaso H, Murakami S, Baba J, Sawa A. Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Jpn J Pharmacol 1998; 77: 147-54.
99. Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol 2004; 498: 135-42.
100. Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats. Psychopharmacology (Berl) 2005a; 182: 104-15.
101. Ye Y, O'Donnell JM. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J Neurochem 1996; 66: 1894-902.
102. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
103. Houslay MD, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-19.
104. Conti AC, Blendy JA. Regulation of antidepressant activity by cAMP response element binding proteins. Mol Neurobiol 2004; 30: 143-55.
105. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183-94.
106. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989; 53: 1644-7.
107. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-72.
108. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
109. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-8.
110. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
111. Branski P, Palucha A, Szewczyk B, Wieronska JM, Pilc A, Nowak G. Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. J Neural Transm 2008; 115: 829-30.
112. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-62.
113. Gur TL, Conti AC, Holden J, Bechtholt AJ, Hill TE, Lucki I, et al. cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci 2007; 27: 7860-8.
114. Andersen PH, Klysner R, Geisler A. Cyclic AMP phosphodiesterase activity in rat brain following chronic treatment with lithium, imipramine, reserpine, and combinations of lithium with imipramine or reserpine. Acta Pharmacol Toxicol (Copenh) 1983; 53: 337-43.
115. D'Sa C, Eisch AJ, Bolger GB, Duman RS. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci 2005: 22: 1463-75.
116. Suda S, Nibuya M, Ishiguro T, Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem 1998; 71: 1554-63.
117. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 1999; 19: 610-8.
118. Ye Y, Conti M, Houslay MD, Farooqui SM, Chen M, O'Donnell JM. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 1997; 69: 2397-404.
119. Ye Y, Jackson K, O'Donnell JM. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 2000; 74: 1257-62.
120. Itoh T, Abe K, Tokumura M, Horiuchi M, Inoue O, Ibii N. Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats. Brain Res 2003; 991:142-9.
121. Miro X, Perez-Torres S, Artigas F, Puigdomenech P, Palacios JM, Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002a; 43: 1148-57.
122. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 1999; 96: 11998-2003.
123. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002; 99:7628-33.
124. Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, et al. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur J Neurosci 2008; 28: 625-32.
125. Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 2008; 197: 115-26.
126. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004; 29: 417-26.
127. Giorgi M, Modica A, Pompili A, Pacitti C, Gasbarri A. The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Behav Brain Res 2004; 154: 99-106.
128. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168:976-82.
129. Miro X, Perez-Torres S, Puigdomenech P, Palacios JM, Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 2002b; 45: 259-69.
130. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001; 111: 106S-12S.
131. Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994; 15: 301-20.
132. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002b; 110: 1045-52.
133. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 2002a; 135: 113-8.
134. Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 2007; 408: 193-201.
135. Zhang KY, Ibrahim PN, Gillette S, Bollag G. Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 2005b; 9: 1283-305.
136. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 1995; 273: 1396-402.
137. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008-14.
138. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 2005; 23: 201-7.
139. Cullen BR. RNAi the natural way. Nat Genet 2005; 37: 1163-5.
140. Zeringue HC, Constantine-Paton M. Post-transcriptional gene silencing in neurons. Curr Opin Neurobiol 2004; 14: 654-9.
141. Li X, Huston E, Lynch MJ, Houslay MD, Baillie GS. Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes. Biochem J 2006; 394: 427-35.
142. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, et al. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 2005; 280: 33178-89
143. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: Predominant role of PDE4D. J Immunol 2007; 178: 4820-31.
144. Waddleton D, Wu W, Feng Y, Thompson C, Wu M, Zhou YP, et al. Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochem Pharmacol 2008; 76: 884-93.
145. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, et al. Discovery of BRL 50481 [3-(N,Ndimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004; 66: 1679-89.
146. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur J Pharmacol 2006; 550: 166-72.
147. Yamamoto S, Sugahara S, Naito R, Ichikawa A, Ikeda K, Yamada T, et al. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur J Pharmacol 2006b; 541: 106-14.
148. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur J Pharmacol 2007; 559: 219-26.
149. Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001; 40: 201-14.
150. Reyes-Irisarri E, Perez-Torres S, Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005; 132: 1173-85.
151. Cashman JR, Voelker T, Johnson R, Janowsky A. Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem 2008; in press.
152. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124-9.
153. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008; 14(17): 1723-42.
154. McSwiggen JA, Seth SA potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. Expert Opin Biol Ther 2008; 8(3): 299-313.
155. Wang QZ, Lv YH, Diao Y, Xu R. The design of vectors for RNAi delivery system. Curr Pharm Des 2008; 14(13): 1327-40.